Genocea biosciences, inc. (GNCA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating activities
Net Income (Loss) Attributable to Parent

-38,950

-27,811

-56,710

-49,573

-42,483

-35,296

-20,806

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

1,097

1,088

1,516

1,813

1,051

469

318

Stock-based compensation

1,837

2,153

4,234

4,147

3,848

2,905

672

Allocation of proceeds to transaction expenses

0

2,115

0

-

-

-

-

Change in fair value of warrant liability

-986

-14,757

0

-

-

725

222

Gain on sale of equipment

29

78

22

0

0

-

-

Write-off of deferred financing fees

110

355

0

-

-

-

-

Non-cash interest expense

504

643

502

481

369

254

22

Asset impairment

-

-

1,028

0

0

-

-

Loss on debt extinguishment

-

-

-

-

-

-435

-200

Changes in operating assets and liabilities
Prepaid expenses and other current assets

803

-53

-12

-

-

-

-

Right of use assets, net of lease liabilities

206

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-97

Prepaid expenses and other current assets

-

-

-

37

-266

442

-27

Other non-current assets

423

989

14

-25

399

-782

1,539

Accounts payable

-1,106

-2,103

491

1,190

-1,431

524

724

Deferred revenue

-

-

-

-235

-670

893

12

Accrued expenses and other liabilities

809

-1,904

1,364

354

1,089

1,147

178

Net cash used in operating activities

-37,734

-41,235

-

-

-

-

-

Net cash used in operating activities

-

-

-47,599

-41,835

-38,360

-27,604

-19,873

Investing activities
Purchases of property and equipment

1,135

241

1,178

2,538

2,784

1,520

389

Proceeds from sale of equipment

48

110

150

0

0

-

-

Net cash used in investing activities

-1,087

-131

-

-

-

-

-

Proceeds from maturities of investments

-

-

36,090

79,313

27,498

0

0

Purchases of investments

-

-

153

26,064

89,651

27,053

0

Net cash used in investing activities

-

-

34,909

50,711

-64,937

-28,573

-389

Financing activities
Proceeds from issuance of common stock, net

54,669

55,458

-

-

-

-

0

Proceeds from equity offerings, net of issuance costs

-

-

0

-

-

-

0

Payment of deferred financing costs

0

127

197

0

0

-

-

Proceeds from long-term debt

0

592

0

-

-

-

-

Proceeds from issuance of preferred stock, net

-

-

-

-

-

-

15,250

Proceeds from issuance of long-term debt, net of issuance costs

-

-

-

0

4,719

11,681

9,965

Repayment of long-term debt

1,919

535

3,149

0

0

10,401

4,245

Proceeds from exercise of stock options

21

0

459

227

383

683

42

Proceeds from the issuance of common stock under ESPP

130

67

180

247

213

93

0

Proceeds from the exercise of warrants

-

-

-

-

-

33

0

Net cash provided by financing activities

52,901

55,455

-

-

-

-

-

Payments made under capital lease

-

-

-

-

-

-

0

Payments for debt issuance costs

-

-

-

-

-

-

58

Net cash provided by financing activities

-

-

-2,461

1,289

100,498

64,027

20,954

Net increase in cash, cash equivalents and restricted cash

14,080

14,089

-15,151

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

10,165

-2,799

7,850

692

Non-cash financing activities and supplemental cash flow information
Cash paid in connection with operating lease liabilities

1,637

0

-

-

-

-

-

Cash paid for interest

1,103

1,074

1,189

-

-

-

-

Cash paid for interest

-

-

-

1,255

897

815

426

Conversion of preferred stock to common stock upon closing of IPO

-

-

-

-

-

81,774

0

Reclassification of prepaid IPO closing costs from non-current assets to additional paid-in capital

-

-

-

-

-

997

0

Reclassification of warrants to additional paid-in capital

-

-

-

-

-

1,381

0

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

180

1,605

Vesting of restricted stock

-

-

-

-

-

-

1

Cashless exercise of warrants

-

-

-

-

-

98

0

Issuance of common stock warrant

-

-

-

-

-

340

0

Equipment purchased under capital lease

-

-

-

-

-

-

0

Property and equipment included in accounts payable and accrued expenses

-

-

-

63

394

0

0

Warrants issued in connection with debt modification

0

190

0

-

-

-

-

Underwritten public offering
Proceeds from equity offerings, net of issuance costs

-

-

246

-

-

-

-